AGE FEATURES OF MOLECULAR-BIOLOGICAL SUBTYPES OF BREAST CANCER
DOI: 10.22138/2500-0918-2020-17-2-187-192
E.A. Novikova, O.V. Kostromina, D.V. Mikhailov, S.L. Leontiev, S.V. Sazonov
FSBEI HE «Ural State Medical University» of the Ministry of Health of the Russian Federation, Yekaterinburg, Russian Federation;
GAUZ SO «Institute of Medical Cell Technologies», Yekaterinburg, Russian Federation
Abstract. Aim. The aim of the study was to determine the presence of peculiarities of the age structure in patients with various surrogate molecular biological subtypes of breast cancer. Materials and research methods. This work analyzes the age-related characteristics of the occurrence of molecular biological subtypes in 499 patients with invasive breast cancer. All cases were divided into 5 molecular biological subtypes based on immunohistochemical studies of hormone receptors, Her2, Ki-67. The average age of the patients was 53.4±0.39 years, the predominant group was patients from 50 to 60 years (37.2% of the total).
Research results. In patients under 40 years old, the triple negative subtype prevailed (44.8%). Luminal A subtype prevailed in the groups 51-60 years old (more than 41.4%) and over 60 years old (39.7%). Luminal B (Her2-) subtype was equally found in all age groups.
Keywords: breast cancer, molecular biological subtypes, immunohistochemistry, age characteristics
Received 11.09.2020
For citation:
Novikova E.A., Kostromina O.V., Mikhailov D.V., Leontiev S.L., SazonovS.V. Age features of molecular-biological subtypes of breast cancer. Vestn. Ural. Med. Akad. Nauki. = Journal of Ural Medical Academic Science. 2020, Vol. 17, no. 2, pp. 187–192. DOI: 10.22138/2500-0918-2020-17-2-187-192 (In Russ)
REFERENCES
1. Sazonov S.V. Quality assurance of molecular biological research in the diagnosis of breast cancer. Yekaterinburg, VUMAN, 2018, 153 p. (In Russ.).
2. Petkau V.V., Bulavina I.S., Sakaeva D.D., Strakhova N.V., Sazonov S.V. Age features of breast cancer. Ural Medical Journal 2012; 4 (96): 24-26. (In Russ.)
3. Leonard R.C., Barrett-Lee P.J., Gosney M.A. et al. Effect of patient age on man agement decisions in breast cancer: consensus from anation al consultation. The Oncologist 2010; 15: 657-664
4. Yancik R., Wesley M.N., Ries L.A. et al. Effect of age and comorbidity in postmenopausal breast cancer patients age 55 years and older. JAMA 2001; Vol 285 (7): 885-892.
5. Novikova EA, Kodintsev AN, Sazonov SV, et al. Expression of the enzyme topoisomerase-II alpha in molecular genetic subtypes of breast cancer. Bulletin of the Ural Medical Academic Science; 2016, no. 4: 30–37. (In Russ.)
6. Cianfrocca M., Goldstein L.J. Prognostic and predictive factors in early-stage breast cancer. The Oncologist 2004; 9: 606-616.
7. Kroger N., Milde-Langosch K., Riethdorf S. et al. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Clin Cancer Res 2006; 12 (1): 158-168.
8. Arutyunyan E.V., A.A. Brilliant, E.A. Novikova, S.V. Sazonov Some patterns of expression of immunohistochemical markers on breast carcinoma cells. Ural Medical Journal; 2014, no.2 (116): 5-8. (In Russ.)
9. Goldhirsch A., Wood W.C., Coates A.S. et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen Internation al Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann of Oncol 2011; Vol. 22: 1736-1747
10. Sazonov SV, Brilliant AA, Brilliant Yu.M. Relationship between the state of proliferative processes and the peculiarities of the receptor apparatus of breast carcinoma tumor cells. Genes and Cells. 2017.T.12. No. 4. S.76-81. (In Russ.)
11. Wolff A.C., Hammond M.E.H., Schwartz J.N. et al. American Society of Clinical Oncology / College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol; 2007, no. 25: 118–145.
12. Semiglazov V.F., Paltuev R.M., Manikhas A.G. and other Clinical guidelines of the ROOM for the diagnosis and treatment of breast cancer. Clinical guidelines ROOM. St. Petersburg. Publishing house «ABV-press». 2015. 504 p. (In Russ.)
13. Shatova Yu.S. Expression of topoisomerase-2α and e-cadherin in different subtypes of breast cancer and the reproductive status of patients. Modern problems of science and education. — 2015. — No. 3. — S. 156-159. (In Russ.).
Authors
Evgeniya A. Novikova
Ural State Medical University
Candidate of Biological Sciences, Senior Lecturer of the Department of Histology, Cytology and Embryology
Russian Federation, 620028, Yekaterinburg, st. Repin, 3
novikova.evgeniya2014@yandex.ru
Olga V. Kostromina
Ural State Medical University
Senior Lecturer, Department of Histology, Cytology and Embryology
Russian Federation, 620028, Yekaterinburg, st. Repin, 3
lelya88.70@mail.ru
Dmitry V. Mikhailov
Ural State Medical University
Student of the medical and preventive faculty
Russian Federation, 620028, Yekaterinburg, st. Repin, 3
hem169@icloud.com
Sergey L. Leontiev
GAUZ SO Institute of Medical Cell Technologies
Director, Doctor of Medical Sciences, Professor
Russian Federation, 620028, Yekaterinburg, st. K. Marks, 20а
ls.04@yandex.ru
Sergey V. Sazonov
Ural State Medical University, Department of Histology, Cytology and Embryology
GAUZ SO Institute of Medical Cell Technologies
Deputy Chief Physician for Science, Doctor of Medical Sciences, Professor
Russian Federation, 620028, Yekaterinburg, st. Repin, 3
prof-ssazonov@yandex.ru